Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:OKUR NASDAQ:RVPH NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.57-1.3%$1.71$1.41▼$5.01$9.23M1.2955,394 shs19,931 shsOKUROnKure Therapeutics$2.75-2.1%$2.43$1.70▼$20.00$38.02M0.4128,496 shs37,314 shsRVPHReviva Pharmaceuticals$0.45-2.2%$0.46$0.30▼$4.28$31.30M-0.052.32 million shs1.23 million shsXLOXilio Therapeutics$0.70+1.4%$0.69$0.62▼$1.70$35.79M-0.15429,082 shs618,532 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-1.26%-4.86%-14.95%-12.08%-55.29%OKUROnKure Therapeutics-2.14%-2.83%+20.61%+10.44%+274,999,900.00%RVPHReviva Pharmaceuticals-2.24%-16.43%-3.04%-53.61%-55.45%XLOXilio Therapeutics+1.39%-0.43%+1.02%-37.99%-13.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics3.1919 of 5 stars3.55.00.00.02.00.81.3OKUROnKure Therapeutics2.854 of 5 stars3.60.00.00.01.92.51.3RVPHReviva Pharmaceuticals2.5946 of 5 stars3.61.00.00.02.33.30.6XLOXilio Therapeutics3.1838 of 5 stars3.72.00.00.04.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50890.42% UpsideOKUROnKure Therapeutics 3.14Buy$32.331,075.76% UpsideRVPHReviva Pharmaceuticals 3.14Buy$5.201,055.56% UpsideXLOXilio Therapeutics 3.33Buy$3.00328.51% UpsideCurrent Analyst Ratings BreakdownLatest APRE, OKUR, XLO, and RVPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025OKUROnKure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$34.008/18/2025RVPHReviva PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $3.008/18/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.008/15/2025RVPHReviva PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/15/2025RVPHReviva PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.008/13/2025OKUROnKure TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/6/2025XLOXilio TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/6/2025XLOXilio TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$2.006/27/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.006/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.006/3/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.08N/AN/A$2.30 per share0.68OKUROnKure TherapeuticsN/AN/AN/AN/A$5.78 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A($0.01) per shareN/AXLOXilio Therapeutics$15.00M2.42N/AN/A$0.14 per share5.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.32N/AN/AN/A-1,645.01%-78.90%-62.67%11/6/2025 (Estimated)OKUROnKure Therapeutics-$52.67M-$4.80N/AN/AN/AN/A-60.52%-55.43%11/6/2025 (Estimated)RVPHReviva Pharmaceuticals-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%11/13/2025 (Estimated)XLOXilio Therapeutics-$58.24M-$0.76N/AN/AN/A-374.79%-399.15%-58.68%11/6/2025 (Estimated)Latest APRE, OKUR, XLO, and RVPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RVPHReviva Pharmaceuticals-$0.15-$0.12+$0.03-$0.12N/AN/A8/14/2025Q2 2025XLOXilio Therapeutics-$0.08-$0.16-$0.08-$0.16$8.21 million$8.21 million8/12/2025Q2 2025APREAprea Therapeutics-$0.77-$0.53+$0.24-$0.53N/A$0.12 million8/12/2025Q2 2025OKUROnKure Therapeutics-$1.23-$1.14+$0.09-$1.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.345.34OKUROnKure TherapeuticsN/A11.1311.13RVPHReviva PharmaceuticalsN/A0.900.90XLOXilio TherapeuticsN/A2.322.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%OKUROnKure Therapeutics90.98%RVPHReviva Pharmaceuticals63.18%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%OKUROnKure Therapeutics2.30%RVPHReviva Pharmaceuticals27.18%XLOXilio Therapeutics5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.83 million5.03 millionNo DataOKUROnKure TherapeuticsN/A13.53 million13.22 millionN/ARVPHReviva Pharmaceuticals568.00 million49.52 millionOptionableXLOXilio Therapeutics7051.83 million49.13 millionNot OptionableAPRE, OKUR, XLO, and RVPH HeadlinesRecent News About These CompaniesXilio Therapeutics (XLO) Has a New Rating from Leerink PartnersAugust 29 at 11:28 PM | theglobeandmail.comXilio Therapeutics Faces Nasdaq Equity Compliance ChallengeAugust 28 at 4:51 PM | tipranks.comXLO | Xilio Therapeutics Inc. Annual Cash Flow Statement | MarketWatchAugust 16, 2025 | marketwatch.comXilio Therapeutics reports Q2 EPS (16c) vs (24c) last yearAugust 15, 2025 | msn.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 15, 2025 | taiwannews.com.twTXilio Revenue Jumps 246 Percent in Q2August 15, 2025 | aol.comAXilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue EstimatesAugust 14, 2025 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform RecommendationAugust 7, 2025 | msn.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comJames Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockJune 19, 2025 | insidertrades.comXilio Therapeutics expands board, elects new directorJune 12, 2025 | investing.comXilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of DirectorsJune 10, 2025 | quiverquant.comQXilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of DirectorsJune 10, 2025 | globenewswire.comXilio Therapeutics Announces Closing of $50.0 Million Public OfferingJune 5, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comXilio Therapeutics Announces Pricing of $50.0 Million Public OfferingJune 2, 2025 | globenewswire.comXilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...June 2, 2025 | stockhouse.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPRE, OKUR, XLO, and RVPH Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.56 -0.02 (-1.26%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$1.60 +0.04 (+2.30%) As of 08/29/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.OnKure Therapeutics NASDAQ:OKUR$2.75 -0.06 (-2.14%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.78 +0.02 (+0.91%) As of 08/29/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.Reviva Pharmaceuticals NASDAQ:RVPH$0.45 -0.01 (-2.24%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.46 +0.01 (+1.33%) As of 08/29/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Xilio Therapeutics NASDAQ:XLO$0.70 +0.01 (+1.39%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.70 0.00 (-0.01%) As of 08/29/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
